Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 400 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ENCODE Clear all
Recruiting Not applicable Interventional

Medical Cannabis and Behavior

NCT06808048
View directory record Official record
Conditions
Chronic Pain Patients, Medical Cannabis Users
Interventions
Cognitive testing, Task-based fMRI measure of face-name and verbal learning
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01335347
View directory record Official record
Conditions
Avian Influenza, Bird Flu
Interventions
ND1.1, Placebo control
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 22, 2026, 7:52 PM EDT
Completed No phase listed Observational Results available

A Pilot Study to Assess the Amnesic Properties of Dexmedetomidine in Pediatric Patients

NCT02354378
View directory record Official record
Conditions
Memory, Dexmedetomidine
Interventions
Dexmedetomidine, Memory Test
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 14 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

staRt: Enhancing Speech Treatment With Smartphone-delivered Biofeedback

NCT04474691
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Traditional articulation treatment, Visual-acoustic biofeedback
Behavioral
Lead sponsor
New York University
Other
Eligibility
8 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 22, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional

Online Rotating Delivery of Perception/Production Enhanced Treatment for Rhotics

NCT06969521
View directory record Official record
Conditions
Speech Sound Disorder
Interventions
Visual acoustic biofeedback: ORDER, Perception Training: ORDER
Behavioral
Lead sponsor
Montclair State University
Other
Eligibility
8 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Montclair, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

NCT00510133
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
GRNVAC1
Biological
Lead sponsor
Asterias Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Maywood, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 22, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional

Flow Detection in Open and Closed Shunt Valve Periods

NCT07478926
View directory record Official record
Conditions
Hydrocephalus
Interventions
Rhaeos Shunt Monitoring System
Device
Lead sponsor
Rhaeos, Inc.
Industry
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1 Interventional

ADVM-022 Intravitreal Gene Therapy for Wet AMD

NCT03748784
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Not applicable Interventional

Improving Well-being by Improving Memory for Treatment for Sleep and Circadian Dysfunction

NCT04373538
View directory record Official record
Conditions
Sleep Disorder, Circadian Dysregulation
Interventions
Trans-C for sleep and circadian function + Memory Support
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
55 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1 Interventional

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

NCT01456104
View directory record Official record
Conditions
Melanoma
Interventions
Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 22, 2026, 7:52 PM EDT
Enrolling by invitation No phase listed Observational

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

NCT04049084
View directory record Official record
Conditions
Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID)
Interventions
autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

NCT03812263
View directory record Official record
Conditions
Leukocyte Adhesion Defect - Type I
Interventions
RP-L201
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
3 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

NCT02780401
View directory record Official record
Conditions
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 7:52 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

NCT05606614
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
6 Years to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

NCT01720316
View directory record Official record
Conditions
Schizo-affective Disorder, Bipolar Disorder
Interventions
Glycine, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

NCT03507686
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

Computerized Information-Processing Bias Retraining in Depressed Adolescents

NCT01147913
View directory record Official record
Conditions
Major Depression
Interventions
Computerized Information-Processing Bias Retraining, Attention Control Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

NCT04123470
View directory record Official record
Conditions
Malignant Melanoma
Interventions
delolimogene mupadenorepvec, atezolizumab
Genetic · Biological
Lead sponsor
Lokon Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Real-time fMRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD

NCT02500719
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Computational Model - Real-time Support Vector Machine
Device
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 22, 2026, 7:52 PM EDT
Completed No phase listed Observational

Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy

NCT00048971
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea, Neutropenia
Interventions
mutation analysis, polymorphic microsatellite marker analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
82
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 22, 2026, 7:52 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Novel Coding Strategies for Children With Cochlear Implants

NCT05203302
View directory record Official record
Conditions
Deafness
Interventions
Single-Electrode Pulse Train, Modulation Detection Threshold (MDT) and Gap Detection Tasks, Sound coding strategy., Electric-only spectral resolution
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

NCT03634007
View directory record Official record
Conditions
Alzheimer Disease, Early Onset Alzheimer Disease
Interventions
LX1001
Biological
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Maitland, Florida • Orlando, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 22, 2026, 7:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency

NCT02991144
View directory record Official record
Conditions
Ornithine Transcarbamylase (OTC) Deficiency
Interventions
scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen
Genetic · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 22, 2026, 7:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

NCT02618915
View directory record Official record
Conditions
Hemophilia B
Interventions
DTX101
Genetic
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 22, 2026, 7:52 PM EDT